TY - JOUR
T1 - Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry
T2 - Enrollment Characteristics and 1-Year Follow-up
AU - Kerr, Kim M.
AU - Elliott, C. Greg
AU - Chin, Kelly
AU - Benza, Raymond L.
AU - Channick, Richard N.
AU - Davis, R. Duane
AU - He, Feng
AU - LaCroix, Andrea
AU - Madani, Michael M.
AU - McLaughlin, Vallerie V.
AU - Park, Myung
AU - Robbins, Ivan M.
AU - Tapson, Victor F.
AU - Terry, Jeffrey R.
AU - Test, Victor J.
AU - Jain, Sonia
AU - Auger, William R.
N1 - Funding Information:
FUNDING/SUPPORT: This registry was funded by an Investigator Sponsored Study Research Grant from Bayer Healthcare Pharmaceuticals awarded to The Regents of the University of California, UC San Diego.Author contributions: K. M. K. takes responsibility for (is the guarantor of) the content of the manuscript, including the data and analysis; K. M. K. J. R. T. W. R. A. R. N. C. M. M. M. I. M. R. and V. J. T. contributed to data acquisition; and K. M. K. C. G. E. K. C. I. M. R. F. H. S. J. and W. R. A. participated in the drafting of the manuscript. K. M. K. G. E. K. C. R. L. B. R. N. C. R. D. D. F. H. A. L. M. M. M. V. V. M. M. P. I. M. R. V. F. T. J. R. T. V. J. T. S. J. and W. R. A. contributed substantially to the study design, data analysis, and interpretation, and all authors participated in the review, editing, and approval of the final version of the manuscript. Financial/nonfinancial disclosures: The authors have reported to CHEST the following: K. M. K. receives research grant paid to institution from Bayer HealthCare; and serves as a consultant for Actelion. K. C. receives research support paid to institution from Actelion, Ironwood, the National Institutes of Health, and SoniVie; served as a consultant and on steering/adjudication committees for Actelion, UCSD (via grant from Bayer), United Therapeutics, Altavant, and Gossamer Bio; and financial/material support from the American Heart Association. R. L. B. serves on the advisory board for Bayer. R. N. C. receives research support paid to institution from Bayer and Actelion; serves as a consultant for Actelion, Bayer, United Therapeutics, and Gossamer; and serves on the speakers bureau for Actelion and Bayer. M. M. M. serves as a consultant for Bayer, Actelion, and Wexler Surgical. V. V. M. reports research support paid to institution from Acceleron, Actelion, Gilead, SoniVie, Reata, and United Therapeutics; and reports scientific consulting for Acceleron, Actelion, Altavant, Caremark, L.L.C. CiVi Biopharma Inc. Gossamer Bio, Liquidia, and United Therapeutics. M. P. serves as a consultant for Bayer, Actelion, Abbott, and AstraZeneca; serves on the speakers bureau for Bayer; and has received travel support from Bayer and Actelion. I. M. R. receives research support paid to institution from Bayer and Complexa; and serves on the advisory board for Bayer and Acceleron Pharma. V. F. T. receives research support paid to institution from the National Institutes of Health, Actelion, Bayer, BMS/Pfizer, United Therapeutics, EKOS/BTG, Inari, and Penumbra; reports advisory board/consulting for Actelion, BMS/Pfizer, United Therapeutics, EKOS/BTG, and Thrombolex; and has received speaking honoraria from Janssen and EKOS/BTG. W. R. A. serves as a consultant for Bayer, Cereno Scientific, and Actelion. None declared (C. G. E. R. D. D. F. H. A. L. J. R. T. V. J. T. S. J.). Role of the sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. Other contributions: The authors thank all principal investigators and research coordinators at the participating registry research sites listed in e-Appendix 1. They are also grateful for the enthusiasm, support, and expertise provided by their colleagues Kathy Feldkircher and Abby Poms at E-Squared Trials and Registries. Additional information: The e-Appendixes and e-Tables can be found in the Supplemental Materials section of the online article.
Funding Information:
FUNDING/SUPPORT: This registry was funded by an Investigator Sponsored Study Research Grant from Bayer Healthcare Pharmaceuticals awarded to The Regents of the University of California , UC San Diego.
Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following: K. M. K. receives research grant paid to institution from Bayer HealthCare; and serves as a consultant for Actelion. K. C. receives research support paid to institution from Actelion, Ironwood, the National Institutes of Health , and SoniVie; served as a consultant and on steering/adjudication committees for Actelion, UCSD (via grant from Bayer), United Therapeutics, Altavant, and Gossamer Bio; and financial/material support from the American Heart Association . R. L. B. serves on the advisory board for Bayer. R. N. C. receives research support paid to institution from Bayer and Actelion; serves as a consultant for Actelion, Bayer, United Therapeutics, and Gossamer; and serves on the speakers bureau for Actelion and Bayer. M. M. M. serves as a consultant for Bayer, Actelion, and Wexler Surgical. V. V. M. reports research support paid to institution from Acceleron, Actelion, Gilead, SoniVie, Reata, and United Therapeutics; and reports scientific consulting for Acceleron, Actelion, Altavant, Caremark, L.L.C., CiVi Biopharma Inc., Gossamer Bio, Liquidia, and United Therapeutics. M. P. serves as a consultant for Bayer, Actelion, Abbott, and AstraZeneca; serves on the speakers bureau for Bayer; and has received travel support from Bayer and Actelion. I. M. R. receives research support paid to institution from Bayer and Complexa; and serves on the advisory board for Bayer and Acceleron Pharma. V. F. T. receives research support paid to institution from the National Institutes of Health , Actelion, Bayer, BMS/Pfizer, United Therapeutics, EKOS/BTG, Inari, and Penumbra; reports advisory board/consulting for Actelion, BMS/Pfizer, United Therapeutics, EKOS/BTG, and Thrombolex; and has received speaking honoraria from Janssen and EKOS/BTG. W. R. A. serves as a consultant for Bayer, Cereno Scientific, and Actelion. None declared (C. G. E., R. D. D., F. H., A. L., J. R. T., V. J. T., S. J.).
Publisher Copyright:
© 2021 The Authors
PY - 2021/11
Y1 - 2021/11
N2 - Background: The United States Chronic Thromboembolic Pulmonary Hypertension Registry (US-CTEPH-R) was designed to characterize the demographic characteristics, evaluation, clinical course, and outcomes of surgical and nonsurgical therapies for patients with chronic thromboembolic pulmonary hypertension. Research Question: What are the differences in baseline characteristics and 1-year outcomes between operated and nonoperated subjects? Study Design and Methods: This study describes a multicenter, prospective, longitudinal, observational registry of patients newly diagnosed (< 6 months) with CTEPH. Inclusion criteria required a mean pulmonary artery pressure ≥ 25 mm Hg documented by right heart catheterization and radiologic confirmation of CTEPH. Between 2015 and 2018, a total of 750 patients were enrolled and followed up biannually until 2019. Results: Most patients with CTEPH (87.9%) reported a history of acute pulmonary embolism. CTEPH diagnosis delays were frequent (median, 10 months), and most patients reported World Health Organization functional class 3 status at enrollment with a median mean pulmonary artery pressure of 44 mm Hg. The registry cohort was subdivided into Operable patients undergoing pulmonary thromboendarterectomy (PTE) surgery (n = 566), Operable patients who did not undergo surgery (n = 88), and those who were Inoperable (n = 96). Inoperable patients were older than Operated patients; less likely to be obese; have a DVT history, non-type O blood group, or thrombophilia; and more likely to have COPD or a history of cancer. PTE resulted in a median pulmonary vascular resistance decline from 6.9 to 2.6 Wood units (P <.001) with a 3.9% in-hospital mortality. At 1-year follow-up, Operated patients were less likely treated with oxygen, diuretics, or pulmonary hypertension-targeted therapy compared with Inoperable patients. A larger percentage of Operated patients were World Health Organization functional class 1 or 2 at 1 year (82.9%) compared with the Inoperable (48.2%) and Operable/No Surgery (56%) groups (P <.001). Interpretation: Differences exist in the clinical characteristics between patients who exhibited operable CTEPH and those who were inoperable, with the most favorable 1-year outcomes in those who underwent PTE surgery. Clinical Trial Registration: ClinicalTrials.gov; No.: NCT02429284; URL: www.clinicaltrials.gov.
AB - Background: The United States Chronic Thromboembolic Pulmonary Hypertension Registry (US-CTEPH-R) was designed to characterize the demographic characteristics, evaluation, clinical course, and outcomes of surgical and nonsurgical therapies for patients with chronic thromboembolic pulmonary hypertension. Research Question: What are the differences in baseline characteristics and 1-year outcomes between operated and nonoperated subjects? Study Design and Methods: This study describes a multicenter, prospective, longitudinal, observational registry of patients newly diagnosed (< 6 months) with CTEPH. Inclusion criteria required a mean pulmonary artery pressure ≥ 25 mm Hg documented by right heart catheterization and radiologic confirmation of CTEPH. Between 2015 and 2018, a total of 750 patients were enrolled and followed up biannually until 2019. Results: Most patients with CTEPH (87.9%) reported a history of acute pulmonary embolism. CTEPH diagnosis delays were frequent (median, 10 months), and most patients reported World Health Organization functional class 3 status at enrollment with a median mean pulmonary artery pressure of 44 mm Hg. The registry cohort was subdivided into Operable patients undergoing pulmonary thromboendarterectomy (PTE) surgery (n = 566), Operable patients who did not undergo surgery (n = 88), and those who were Inoperable (n = 96). Inoperable patients were older than Operated patients; less likely to be obese; have a DVT history, non-type O blood group, or thrombophilia; and more likely to have COPD or a history of cancer. PTE resulted in a median pulmonary vascular resistance decline from 6.9 to 2.6 Wood units (P <.001) with a 3.9% in-hospital mortality. At 1-year follow-up, Operated patients were less likely treated with oxygen, diuretics, or pulmonary hypertension-targeted therapy compared with Inoperable patients. A larger percentage of Operated patients were World Health Organization functional class 1 or 2 at 1 year (82.9%) compared with the Inoperable (48.2%) and Operable/No Surgery (56%) groups (P <.001). Interpretation: Differences exist in the clinical characteristics between patients who exhibited operable CTEPH and those who were inoperable, with the most favorable 1-year outcomes in those who underwent PTE surgery. Clinical Trial Registration: ClinicalTrials.gov; No.: NCT02429284; URL: www.clinicaltrials.gov.
KW - CTEPH
KW - chronic thromboembolic pulmonary hypertension
KW - pulmonary hypertension
KW - registry
KW - venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85116045079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116045079&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2021.05.052
DO - 10.1016/j.chest.2021.05.052
M3 - Article
C2 - 34090871
AN - SCOPUS:85116045079
SN - 0012-3692
VL - 160
SP - 1822
EP - 1831
JO - Diseases of the chest
JF - Diseases of the chest
IS - 5
ER -